HPQ CEO Explains How €1 Million in French Defence Funding Could Accelerate METAGENE™ Commercialization
In a new interview, HPQ CEO Bernard Tourillon discusses the commercial potential of METAGENE™, following nearly €1 million in funding secured by Novacium and its partners through France’s RAPID defence innovation program.
During the interview, Bernard presents a preview of HPQ’s new METAGENE™ investor presentation, explaining how the technology could address one of hydrogen’s biggest economic challenges: the cost of transporting and delivering hydrogen to end users.
Key Highlights from the Interview
✅ A different approach to hydrogen production: METAGENE™ generates hydrogen directly at the point of use using recycled aluminum-silicon fuel and water, without requiring external electricity.
✅ Potential cost advantages: Bernard discusses estimated on-site hydrogen production costs of €20–€30/kg, compared with delivered hydrogen costs exceeding €50/kg in certain European markets.
✅ A potential recurring revenue model: HPQ and Novacium envision commercializing METAGENE™ through equipment sales, industrial partnerships and ongoing fuel supply, potentially reducing the need for substantial manufacturing capital investments.
✅ A clearer commercialization timeline: Bernard outlines the team’s objective of developing its first operational prototype by Q3–Q4 2027, ahead of the full 30-month RAPID project timeline.
By Watching the Interview, You’ll Learn:
✔️ Why France’s decision to fund 80% of the €1.2 million project represents an important milestone for Novacium.
✔️ How METAGENE™ could serve civilian and military applications, including drones, remote industrial operations, mobile hydrogen refueling and off-grid power systems.
✔️ Why Bernard believes the technology’s commercial opportunity extends beyond hydrogen production to equipment sales and recurring fuel revenues.
✔️ What needs to happen before HPQ and Novacium can begin pursuing commercial orders, and why a future standalone business structure could eventually be considered.
The discussion offers shareholders a closer look at METAGENE™’s economics, potential business model and development roadmap, including insights not covered in the original press release.
WATCH THE FULL INTERVIEW: